Covidvaccine
Novavax - Wassup?Novavax NVAX is actually lining up pretty well... from about 240, it tanked to 40, and on Friday, it gained 11% to close the week at 57.15.
This caught my attention as it cleanly broke out of trendlines, breaking out also from a bearish divergence, on BOTH the weekly and daily chart.
IMHO, it appears to be in technical and fractal alignment.
Weekly chart bounced off a major support two weeks ago, and the last week continued the previous week's bullish end. On the daily chart, Friday's close was the highest daily close in about 5 weeks. with a strong candle closing draws obvious bullish attention.
Target 80, then 125.
Support at 53 and 50.
ARDS upside potentialARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19.
And the Market Cap is only 23.892Mil.
In my opinion this stock can double in trice anytime, their pipeline is highly undervalued.
ARDS receives grant from the Bill & Melinda Gates FoundationARDS Aridis Pharmaceuticals received a grant award from the Bill & Melinda Gates Foundation to evaluate the application of Aridis' inhaled formulation technology to deliver cost-effective monoclonal antibodies (mAbs) against influenza and SARS-CoV2.
Aridis Pharmaceuticals is a stock with a mk cap of only 28.249Mil.
Before Aridis, Bill & Melinda Gates Foundation Covid-19 Response investments were in giant companies like: Abbott Laboratories, Gavi / Serum, Lilly mAb, SD Biosensor, UNICEF VII and World Health Organization.
AstraZeneca PLC ( AZN ) has a stake in Aridis Pharmaceuticals.
CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune.
Aridis Pharmaceuticals can be a potential buyout for AZN .
Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment!
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
With this investment, i think ARDS is at least an 100Mil mk cap stock.
So 4X from here.
ARDS 1250% upside potential according to H.C. Wainwright !!!Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment!
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap of only 21.22Mil
52 Week Range 1.49 - 8.47
You can buy the all time low now!
ADGI Potential Neutralizing Activity Against Covid-19 VariantsAdagio Therapeutics announced its lead monoclonal antibody has neutralization activity against the Omicron variant of SARS-CoV-2.
Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19.
Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials.
My price target is the $14.5 resistance.
ARDS Covid-19 Antibody Cocktail | Massive Bullish DivergenceThe chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon!
Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap 27.124Mil
52 Week Range 1.89 - 8.47
I think this might be our 10X stock for 2022.
ARDS Covid-19 First-in-Class Antibody | +818% Analyst Rating ! Analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS, told investors Wednesday that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap of only 32.605Mil
52 Week Range 1.89 - 8.47
I think this might be our 10X stock for 2022.
Happy New Year!
NOVAVAX Fractal and Symmetric trianglefirst of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)
NOVAVAX BARR into Symmetric trainglefirst of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)
OCGN COVAXIN Robust Immune Memory to COVID-19 and VariantsNew Data suggest COVAXIN (BBV152) may provide protection against current and future variants!
data from a Phase 3 trial that included nearly 25,800 participants: 77.8% overall efficacy, 93.4% efficacy against severe illness and 65.2% efficacy against the Delta variant.
52 Week Range 0.28 - 18.77
My price target is the 10.30usd resistance.
$VIR entry PT 42-44 Long term Target PT 200HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200
CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants
KEY POINTS:
- Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmithKline “stands up well” to all variants.
- The companies announced contracts to sell $1 billion worth of sotrovimab to the U.S. government. The FDA has already granted sotrovimab an emergency use authorization to treat mild to moderate Covid infections.
- Though Scangos said the delta variant is “going to be with us for a while,” he added that sotrovimab could likely protect against new variants that emerge.
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
PFE Pfizer to All Time HighIf you haven`t bought at my first call, when PFE was $40:
Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five.
Still low PE Ratio (TTM) 15.42
Decent Forward Dividend & Yield 1.56 (2.89%)
The stock jumped also on the promise of its antiviral pill!
For me is a Buy even at this level!
NRXP COVID-19 Vaccine Effectiveness Against Delta VariantNRx Pharmaceuticals announced that its BriLife COVID-19 Vaccine is Effectiveness Against Delta Variant.
Information was released by Israel Institute for Biological Research.
Since the pandemic isn`t over, there is a place in the market for new developers that have effective vaccines.
I consider this a premium call, the upside i see here is 400%, or the 24usd resistance.
NRXP 52 Week Range 4.07 - 76.99usd. Now the price is 6.75usd.
Is this a buy or not?
Market Cap of only 396.97Mil
ascending channel, gains after earnings, short-time bullishNot financial advice!
We can clearly see the ascending channel of this stock. Even though the stock is running for quite some time now, I don't think it will actually stop before we see $54,XX.
After last earnings the stock gained about 20% and reached the top of channel after 14 trading days. From my point of view, since the last earnings reported were even better and the Covid-medication is on the way, there is no doubt that it will touch the top of channel again within a few days. If it does, it magically gained about 20% within 14 trading days after earnings.
Watch the last high closely, as PFE may get rejected there.
Not financial advice!
HGEN in EU Commission 10 Most Promising Treatments for COVID-19!European Commission’s independent experts selected Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19!
CEO of Humanigen said today: "We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19".
In the same list you can see Pfizer, Roche, Astra Zeneca and Eli Lilly! Humanigen is the smallest company.
Institutions loaded big on this dip of Humanigen, Inc. (HGEN), 132Mil in the last quarter!
On 8/23/2021 Morgan Stanley reported an increased ownership in HGEN by +1,884.6%!
Biggest shareholder is Blackrock with 3,037,693 shares worth $52.80Mil, which increased its position by +283.5% for a total ownership of 5.141% of Humanigen.
So Blackrock paid an average of 17.3usd per share!
The price of the stock is now 6.60usd!
H.C. Wainwright’s Joseph Pantginis rates HGEN a Buy along with a $28 price target and said the market overreacted on that selloff.
My price target is the 16.3usd resistance!
NRXP | in search for the next MRNA After a perfect touch of the .618 Fib retracement level, now NRXP is ready to aim higher!
Get ready for action!
My first price target is 35usd.
Today NRx was granted Fast Track Designation by the U.S. Food and Drug Administration for ZYESAMI (aviptadil) for the treatment of Critical COVID-19 with respiratory failure!
NRx Pharmaceuticals has also a Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife COVID Vaccine.
NRx Pharmaceuticals has Successful Commercial Formulation for ZYESAMI (aviptadil) and Stockpiling of COVID-19 Medication Subject to Regulatory Approval.
ZYESAMI Helps Prevent "Cytokine Storm" in Patients with COVID-19
VXRT Vaxart Covid-19 VaccineOn 6/11/2021 Piper Sandler brokerage Initiated Coverage giving a price target of $18.00
VXRT Vaxart today announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier. (prnewswire.com)
This is in line with my previews chart:
DYAI Covid-19 Vaccine for the African ContinentDyadic International signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium.
The Rubic Consortium is made up of promoters of the project representing public health, medical, academia, vaccine technology, technology transfer and economics sectors.
Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreement.
Provides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III clinical trials.
Establishes co-development basis for researching, developing and manufacturing multiple other C1 produced vaccines in addition to DYAI-100.
Intends to reduce African dependence on foreign vaccine suppliers.
Combined with previous C1 COVID-19 vaccine collaborations in India and South Korea (including Southeast Asia), this agreement further supports the potential for C1 produced COVID-19 immunization coverage to more than 40% of the world’s population. (rubicconsortium.co.za)
Now what is the potential for DYAI???
The 52 Week Range is 3.1500 - 9.1900
Now the price is 3.89usd, so close to the lower end.
The market cap is only 107Mil
The biggest owner, 4.744%, is BlackRock Inc. which reported on 5/7/2021 1,307,205 shares on DYAI for a market value of $7.18Mil.
if we make an average, Blackrock bought DYAI at 5.5usd per share. and i don`t think it will sell for less, especially with new COVID-19 vaccine coming.
The second important owner is Vanguard Group Inc., which has 709,698 shares at a market value of $4.44Mil. they bought DYAI at 6.25usd and didn`t panic sell when the stock went to 2.5usd!
My short term price target is 6.5usd, but on the long run, depending on the efficacy of the vaccine, this company can worth Billions!
Just remember MRNA before it made 25X!
BIOV -- FDA approval for COVID-19 clinical trialsBiotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study:
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2.
The FDA found the Chemistry, Manufacturing and Controls, and other elements of the clinical development program proposed by BioVaxys to be acceptable and provided guidance and feedback supportive of BioVaxys' clinical development plans for CoviDTH. In addition, the FDA indicated that animal toxicity studies for CoviDTH were not required and that the Company could start its clinical development program with a combined Phase I/II study. Based on this feedback, BioVaxys will begin preparation of an IND application to support a Phase I/II safety, dosing, and efficacy study.
BioVaxys submitted a Pre-Investigational New Drug ("IND") meeting request and briefing package with the FDA's Center for Biologics Evaluation and Research (CBER) for CoviDTH earlier this year. The Pre-IND review is a critical step in the US regulatory approval process, as it affords an opportunity for study sponsor companies to seek clarification from the FDA on clinical trials design, clinical materials manufacturing, quality controls, etc.
"With the guidance we received from this FDA review, BioVaxys is now able to begin preparing its IND," stated BioVaxys President and Chief Operating Officer Ken Kovan. He adds "Although the FDA has indicated that our planned animal tox study is discretionary, we will likely continue with the animal tox study of CoviDTH as it does not interfere with the development time frame and may in fact provide useful data."
James Passin, BioVaxys CEO, stated, "We are pleased to advance CoviDTH towards clinical trials, as we believe that mass screening for T cell immunity to Covid-19 will represent a critical tool for public health authorities to address the continued pandemic, as Covid variants continue to circulate and major governments in the southern hemisphere enact new lockdown policies."
The Company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain Covid-19 (SARS-CoV-2) at this time.
NRBO 400% Upside Potential | Covid-19 TreatmentOn 4/20/2021 HC Wainwright brokerage Reiterated Rating to Buy and a Price Target of $16.00 for NRBO
But how come? What`s the catalyst? Why NeuroBo Pharmaceuticals was up 40% yesterday?
Richard J. Kang, CEO: "Throughout the first quarter of 2021, we continued to make progress advancing the 60-patient Phase 2/3 clinical trial of our lead drug candidate, ANA001, a proprietary oral niclosamide formulation, as a treatment for moderate to severe COVID-19."
"we expect to report preclinical in vitro data demonstrating Gemcabene's ability to treat COVID-19 variants alone and in combination with ANA001."
"NeuroBo has the financial foundation to fund operations at the current level into the fourth quarter of 2021 and we expect to achieve a number of value-creating milestones with our COVID-19 programs in the coming months."
Besides the Covid-19 treatment, NeuroBo Pharmaceuticals has a current portfolio of four drug candidates focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases.
The Market Cap if only 88.473Mil at the time or writing!
In search for the next BNTX, MRNA and NVAX !!Since Covid-19 is here to stay with us with its variants and the vaccines don`t offer lifetime protection, this means that there is room for other companies to develop a better vaccine to address the problem.
And the gains in vaccines stock are quite similar to cryptocurrencies year over year.
From all time low to all time high, BNTX made 19X, MRNA 24X and NVAX 66X.
My question for you is the following: which is the next vaccine developer to make at least 10X our money?? I`m looking forward to discover with you the next big vaccine developer!
And i have a presumption or two which i already shared in my group. And those were the fundamentals i was searching for: data submitted to FDA for Emergency Use Authorization, Phase 3, low Market cap - under 1Bil, on the lower end of 52 Week Range, other drugs in the pipeline, high intraday volume.
NVAX Novavax Analyst RatingsOn 6/15/2021 Cantor Fitzgerald brokerage Boosted the Price Target from Reduce to Overweight $217.00 to $272.00
On 5/18/2021 JPMorgan Chase & Co. brokerage Reiterated Rating from Overweight to Neutral $285.00 to $161.00
On 5/12/2021 B. Riley brokerage Lowered the Price Target from $365.00 to $286.00
On 5/12/2021 HC Wainwright brokerage Lowered the Price Target from $317.00 to $294.00
My personal price target is $240.
Looking forward to read your opinion.
